Neurological Clinical Research Institute

The Neurological Clinical Research Institute (NCRI) at Mass General is an academic research organization composed of innovative researchers experienced and passionate about designing, developing, facilitating, and conducting multicenter clinical trials in neurological diseases. Our goal is to develop new treatments for the patients we care for and for patients around the globe. We have particular expertise in ALS, Parkinson’s disease and other neurodegenerative diseases. The unique strength of the NCRI is our institute’s position within one of the country’s largest hospital-based Neuroscience Research departments. The NCRI is able to leverage subspecialty experience from the department of neurology’s 200+ clinical faculty to provide the scientific leadership and collaborative approaches required to meet any complex challenges presented. Our world-renowned Harvard Medical School-based faculty are able to challenge conventional approaches and explore innovation, accelerating the translation of scientific discovery into better care for patients everywhere. Co-founded in 1994 by Dr. Merit Cudkowicz and Dr. Steven Greenberg to conduct clinical research in neurological disorders, the NCRI develops, designs, supports and manages innovative observational and interventional trials for neurological disorders. In collaboration with the Mass General Biostatistics Center, the NCRI has an impressive record of rapidly and efficiently leading small and large multi-center, international clinical trials including randomized, double-blind, double-dummy and open label designs. Mission The mission of the Neurological Clinical Research Institute (NCRI) is to accelerate translational research in neurological disorders by initiating clinical development of novel therapies and leading trials of these compounds. We strive to be at the cutting edge of innovative trial design to accelerate therapy development by creating new trial methodology, discovering novel biomarkers and refining outcome measures.